JP2005508332A - 薬剤を送達するための、輸送タンパク質とコンジュゲートコバラミンとの同時投与 - Google Patents

薬剤を送達するための、輸送タンパク質とコンジュゲートコバラミンとの同時投与 Download PDF

Info

Publication number
JP2005508332A
JP2005508332A JP2003530309A JP2003530309A JP2005508332A JP 2005508332 A JP2005508332 A JP 2005508332A JP 2003530309 A JP2003530309 A JP 2003530309A JP 2003530309 A JP2003530309 A JP 2003530309A JP 2005508332 A JP2005508332 A JP 2005508332A
Authority
JP
Japan
Prior art keywords
administration
cobalamin
independently
transport protein
bond
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2003530309A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005508332A5 (https=
Inventor
コリンズ，ダグラス・エイ
Original Assignee
メイオウ・フアウンデーシヨン・フオー・メデイカル・エジユケイシヨン・アンド・リサーチ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by メイオウ・フアウンデーシヨン・フオー・メデイカル・エジユケイシヨン・アンド・リサーチ filed Critical メイオウ・フアウンデーシヨン・フオー・メデイカル・エジユケイシヨン・アンド・リサーチ
Publication of JP2005508332A publication Critical patent/JP2005508332A/ja
Publication of JP2005508332A5 publication Critical patent/JP2005508332A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0497—Organic compounds conjugates with a carrier being an organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7135—Compounds containing heavy metals
    • A61K31/714—Cobalamins, e.g. cyanocobalamin, i.e. vitamin B12
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug
    • A61K47/551—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug one of the codrug's components being a vitamin, e.g. niacinamide, vitamin B3, cobalamin, vitamin B12, folate, vitamin A or retinoic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H23/00—Compounds containing boron, silicon or a metal, e.g. chelates or vitamin B12

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
JP2003530309A 2001-09-28 2002-09-30 薬剤を送達するための、輸送タンパク質とコンジュゲートコバラミンとの同時投与 Pending JP2005508332A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US32618301P 2001-09-28 2001-09-28
PCT/US2002/031038 WO2003026674A1 (en) 2001-09-28 2002-09-30 Coadministration of transport protein with conjugated cobalamin to deliver agents

Publications (2)

Publication Number Publication Date
JP2005508332A true JP2005508332A (ja) 2005-03-31
JP2005508332A5 JP2005508332A5 (https=) 2006-01-05

Family

ID=23271139

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2003530309A Pending JP2005508332A (ja) 2001-09-28 2002-09-30 薬剤を送達するための、輸送タンパク質とコンジュゲートコバラミンとの同時投与

Country Status (5)

Country Link
US (2) US20030144198A1 (https=)
EP (1) EP1435973A4 (https=)
JP (1) JP2005508332A (https=)
CA (1) CA2461705A1 (https=)
WO (1) WO2003026674A1 (https=)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007505144A (ja) * 2003-09-10 2007-03-08 インフラブロック・ファーマシューティカルス・インコーポレーテッド 抗腫瘍療法のためのコバラミン結合体
JP2013129670A (ja) * 2007-08-30 2013-07-04 Technische Univ Muenchen 癌の画像化と処置
JP2016528299A (ja) * 2013-08-22 2016-09-15 ロバート・ドイルＲｏｂｅｒｔ ＤＯＹＬＥ ビタミンｂ１２および内因子を含む組成物およびその使用方法

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5739313A (en) 1995-11-13 1998-04-14 Regents Of The University Of Minnesota Radionuclide labeling of vitamin B12 and coenzymes thereof
US6806363B1 (en) * 1999-04-16 2004-10-19 Mayo Foundation For Medical Education & Research Cobalamin conjugates useful as antitumor agents
WO2001028595A1 (en) 1999-10-15 2001-04-26 Mayo Foundation For Medical Education And Research Cobalamin conjugates useful as imaging and therapeutic agents
US7591995B2 (en) * 1999-10-15 2009-09-22 Mayo Foundation For Medical Education And Research Cobalamin conjugates useful as imaging and therapeutic agents
CA2427146A1 (en) * 2000-10-25 2002-07-18 Mayo Foundation For Medical Education And Research Transcobalamin binding conjugates useful for treating abnormal cellular proliferation
US7101842B2 (en) * 2001-05-16 2006-09-05 Faulk Pharmaceuticals, Inc. Targeted delivery of drugs for the treatment of parasitic infections
US20030018009A1 (en) * 2001-06-20 2003-01-23 Collins Douglas A. Adenosyl-cobalamin fortified compositions
JP2005508332A (ja) * 2001-09-28 2005-03-31 メイオウ・フアウンデーシヨン・フオー・メデイカル・エジユケイシヨン・アンド・リサーチ 薬剤を送達するための、輸送タンパク質とコンジュゲートコバラミンとの同時投与
EP1670428A4 (en) * 2003-10-10 2008-03-12 Univ Southern California HYBRID PROTEINS G-CSF-TRANSFERRIN
AU2004303528B2 (en) * 2003-12-22 2009-05-28 Paul Scherrer Institut Cobalamine derivatives useful for diagnosis and treatment of abnormal cellular proliferation
ES2282062T1 (es) 2004-06-04 2007-10-16 Teva Pharmaceutical Industries Ltd. Composicion farmaceutica que contiene irbesartan.
US7351423B2 (en) 2004-09-01 2008-04-01 Depuy Spine, Inc. Musculo-skeletal implant having a bioactive gradient
US8535750B2 (en) * 2005-05-17 2013-09-17 Cargill, Incorporated Granular lecithins, granular lysolecithins, process for their production and compositions containing them
WO2006133257A2 (en) * 2005-06-06 2006-12-14 The Regents Of The University Of California Use of cis-epoxyeicosatrienoic acids and inhibitors of soluble epoxide hydrolase to reduce cardiomyopathy
JP2009504767A (ja) * 2005-08-17 2009-02-05 フレミング・アンド・カンパニー・ファーマシューティカルズ ビタミンｂ１２鼻用スプレーおよび使用方法
US20100178245A1 (en) * 2009-01-13 2010-07-15 Arnsdorf Morton F Biocompatible Microbubbles to Deliver Radioactive Compounds to Tumors, Atherosclerotic Plaques, Joints and Other Targeted Sites
WO2012030745A1 (en) * 2010-08-30 2012-03-08 Access Pharmaecuticals, Inc MULTIVITAMIN TARGETING OF RNAi THERAPEUTICS
US8877221B2 (en) 2010-10-27 2014-11-04 Warsaw Orthopedic, Inc. Osteoconductive matrices comprising calcium phosphate particles and statins and methods of using the same
US9107983B2 (en) 2010-10-27 2015-08-18 Warsaw Orthopedic, Inc. Osteoconductive matrices comprising statins
US9308190B2 (en) 2011-06-06 2016-04-12 Warsaw Orthopedic, Inc. Methods and compositions to enhance bone growth comprising a statin
DE102012014581A1 (de) * 2012-07-24 2014-01-30 Azoba Health Care Ag Vitaminzubereitung
US20160008342A1 (en) 2014-06-16 2016-01-14 The Regents Of The University Of California Methods of improving cell-based therapy
WO2016187499A1 (en) * 2015-05-20 2016-11-24 Syracuse University Improved glycemic control using intrinsic factor bound to a vitamin b12 conjugate of a glucagon-like peptide- 1 receptor agonist
US11207415B2 (en) 2016-04-15 2021-12-28 Syracuse University Peptide drug improvement using vitamin B12 and haptocorrin binding substrate conjugates
US20190231925A1 (en) * 2018-01-31 2019-08-01 Changchun Ja Biotech. Co., Ltd. Heparin sodium supported hydrogel sustained-release paster
WO2020113130A1 (en) * 2018-11-29 2020-06-04 The Trustees Of Dartmouth College Tumor targeting vitamin b12 derivatives for x-ray activated chemotherapy
WO2022006436A2 (en) * 2020-07-01 2022-01-06 Bioaffinity Technologies, Inc. Compositions and methods for cellular delivery of rna

Family Cites Families (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR1578734A (https=) * 1967-11-28 1969-08-22
US3936440A (en) * 1974-05-22 1976-02-03 Drexel University Method of labeling complex metal chelates with radioactive metal isotopes
US3981863A (en) * 1975-02-25 1976-09-21 Micromedic Diagonistics, Inc. Cyanocobalamin derivatives
US4279859A (en) * 1977-07-21 1981-07-21 Becton Dickinson & Company Simultaneous radioassay of folate and vitamin B12
US4209614A (en) * 1978-05-30 1980-06-24 E. R. Squibb & Sons, Inc. Vitamin B12 derivative suitable for radiolabeling
US4301140A (en) * 1979-12-14 1981-11-17 G. D. Searle & Co. Radiopharmaceutical method for monitoring kidneys
US4283342A (en) * 1980-01-31 1981-08-11 University Of Delaware Anticancer agents and methods of manufacture
CA1180273A (en) * 1981-06-22 1985-01-02 Technicon Instruments Corporation Assay of vitamin b in12 xx
US4672028A (en) * 1984-05-23 1987-06-09 Icn Micromedic Systems, Inc. Compositions and method for simultaneous multiple array of analytes using radioisotope chelate labels
NZ217821A (en) * 1985-10-10 1989-07-27 Biotech Australia Pty Ltd Oral delivery system; complex of active agent and vitamin b12 or analogue thereof
US4987071A (en) * 1986-12-03 1991-01-22 University Patents, Inc. RNA ribozyme polymerases, dephosphorylases, restriction endoribonucleases and methods
US5807832A (en) * 1987-06-09 1998-09-15 Biotech Australia Pty Limited Oral delivery of biologically active substances bound to vitamin B12
US5057301A (en) * 1988-04-06 1991-10-15 Neorx Corporation Modified cellular substrates used as linkers for increased cell retention of diagnostic and therapeutic agents
US5405839A (en) * 1989-02-28 1995-04-11 Teijin Limited Vitamin B12 derivative, preparation process thereof, and use thereof
US4959356A (en) * 1989-05-26 1990-09-25 The United States Of America As Represented By The United States Department Of Energy Porphyrins for boron neutron capture therapy
US6395492B1 (en) * 1990-01-11 2002-05-28 Isis Pharmaceuticals, Inc. Derivatized oligonucleotides having improved uptake and other properties
US6153737A (en) * 1990-01-11 2000-11-28 Isis Pharmaceuticals, Inc. Derivatized oligonucleotides having improved uptake and other properties
US6001577A (en) * 1998-06-08 1999-12-14 Nexstar Pharmaceuticals, Inc. Systematic evolution of ligands by exponential enrichment: photoselection of nucleic acid ligands and solution selex
US5372808A (en) * 1990-10-17 1994-12-13 Amgen Inc. Methods and compositions for the treatment of diseases with consensus interferon while reducing side effect
US5308606A (en) * 1991-01-30 1994-05-03 The Dow Chemical Company Method of treating and/or diagnosing soft tissue tumors
CA2084194C (en) * 1991-04-02 2003-05-20 Gregory John Russell-Jones Oral delivery systems for microparticles
US5187107A (en) * 1991-06-27 1993-02-16 Bio-Rad Laboratories, Inc. B12 enzyme imunoassay and sample pretreatment
US5405598A (en) * 1992-02-24 1995-04-11 Schinazi; Raymond F. Sensitizing agents for use in boron neutron capture therapy
EP1138334A3 (en) * 1992-06-09 2002-04-03 Neorx Corporation Pretargeting methods and compounds
US5286853A (en) * 1992-09-11 1994-02-15 Boron Biologicals, Inc. Boron-gadolinium compounds and method of conducting imaging and/or neutron capture therapy with same
US5548064A (en) * 1993-05-24 1996-08-20 Biotech Australia Pty Limited Vitamin B12 conjugates with EPO, analogues thereof and pharmaceutical compositions
US5449720A (en) * 1993-05-24 1995-09-12 Biotech Australia Pty Limited Amplification of the VB12 uptake system using polymers
US5599796A (en) * 1993-12-02 1997-02-04 Emory University Treatment of urogenital cancer with boron neutron capture therapy
US6180766B1 (en) * 1993-12-02 2001-01-30 Raymond F. Schinazi Nucleosides and oligonucleotides containing boron clusters
CA2187346C (en) * 1994-04-08 2010-06-29 A. Charles Morgan, Jr. Receptor modulating agents and methods relating thereto
US5869465A (en) * 1994-04-08 1999-02-09 Receptagen Corporation Methods of receptor modulation and uses therefor
US5840880A (en) * 1994-04-08 1998-11-24 Receptagen Corporation Receptor modulating agents
US5630786A (en) * 1994-06-27 1997-05-20 Ionix Corporation Boron neutron capture enhancement of fast neutron therapy
JPH11505504A (ja) * 1994-06-27 1999-05-21 イオニックス・コーポレーション ホウ素を含有するホルモン類似体及びホルモン受容体を有する細胞をイメージング若しくは殺すためにこれらを使用する方法
US5574018A (en) * 1994-07-29 1996-11-12 Amgen Inc. Conjugates of vitamin B12 and proteins
US5736392A (en) * 1995-06-07 1998-04-07 Life Technologies, Inc. Peptide-enhanced cationic lipid transfections
DE69636112T2 (de) * 1995-08-30 2006-12-14 Toray Industries, Inc. Verfahren zum testen von myocarditis und cardiomyopathie
US5877165A (en) * 1995-11-02 1999-03-02 Brookhaven Science Associates Boronated porhyrins and methods for their use
US5739313A (en) * 1995-11-13 1998-04-14 Regents Of The University Of Minnesota Radionuclide labeling of vitamin B12 and coenzymes thereof
ATE298344T1 (de) * 1996-08-27 2005-07-15 Univ Utah Res Found Biokonjugate und verabreichung von bioaktiven substanzen
WO1998011900A2 (en) * 1996-09-18 1998-03-26 Sarill William J Compositions containing cobalamin and amino acids
US6056973A (en) * 1996-10-11 2000-05-02 Sequus Pharmaceuticals, Inc. Therapeutic liposome composition and method of preparation
US5879465A (en) * 1996-12-20 1999-03-09 Mckevitt; Patrick Method and apparatus for descaling hot rolled stainless steel strip
AUPO888097A0 (en) * 1997-08-29 1997-09-25 Biotech Australia Pty Limited Cross-linked particles
WO1999013719A1 (en) * 1997-09-18 1999-03-25 Gene Therapy Systems, Inc. Chemical modification of dna using peptide nucleic acid conjugates
US6093701A (en) * 1997-12-12 2000-07-25 Mirus, Inc. Method for covalent attachment of compounds to genes
US5936082A (en) * 1997-12-30 1999-08-10 The University Of Akron Metallocorrinoids as biologically compatible carriers of pharmacological agents
US6183723B1 (en) * 1998-01-21 2001-02-06 Mcw Research Foundation Transcobalamin mediated transport of vitamins B12 in intrinsic factor or receptor deficient patient
AUPP405098A0 (en) * 1998-06-12 1998-07-02 Access Pharmaceuticals Australia Pty Limited Novel methods of preparation of vitamin b12 derivatives suitable for conjugation to pharmaceuticals
DE19905094C1 (de) * 1999-02-01 2000-10-12 Schering Ag Gadolinium (III)-Komplexe sowie ihre Verwendung für Zweischritt Strahlentherapieformen und diese enthaltende pharmazeutische Mittel
US6071545A (en) * 1999-02-03 2000-06-06 Vyrex Corporation Metallic oligopeptide complexes
US6017902A (en) * 1999-02-25 2000-01-25 Brookhaven Science Associates Boron containing amino acid compounds and methods for their use
US6806363B1 (en) * 1999-04-16 2004-10-19 Mayo Foundation For Medical Education & Research Cobalamin conjugates useful as antitumor agents
KR20020032421A (ko) * 1999-04-16 2002-05-03 메이오 파운데이션 포 메디칼 에쥬케이션 앤드 리써치 항암제로서 유용한 코발라민 컨쥬게이트
JP2003512338A (ja) * 1999-10-15 2003-04-02 メイオウ・フアウンデーシヨン・フオー・メデイカル・エジユケイシヨン・アンド・リサーチ 造影剤および抗腫瘍薬として有用なコバラミン結合体
WO2001028595A1 (en) * 1999-10-15 2001-04-26 Mayo Foundation For Medical Education And Research Cobalamin conjugates useful as imaging and therapeutic agents
US6165789A (en) * 1999-10-27 2000-12-26 Isis Pharmaceuticals, Inc. Antisense modulation of hnRNP A1 expression
US6159734A (en) * 2000-01-18 2000-12-12 Isis Pharmaceuticals, Inc. Antisense modulation of peroxisome proliferator-activated receptor gamma expression
US20020002146A1 (en) * 2000-02-11 2002-01-03 Halevie-Goldman Brian D. Compositions and methods for the production of S-adenosylmethionine within the body
US6962906B2 (en) * 2000-03-14 2005-11-08 Active Motif Oligonucleotide analogues, methods of synthesis and methods of use
WO2001092288A2 (en) * 2000-05-31 2001-12-06 Mayo Foundation For Medical Education And Research Cobalamin compounds useful as antibiotic agents and as imaging agents
AU6972901A (en) * 2000-05-31 2001-12-11 Mayo Foundation Cobalamin compounds useful as cardiovascular agents and as imaging agents
CA2427146A1 (en) * 2000-10-25 2002-07-18 Mayo Foundation For Medical Education And Research Transcobalamin binding conjugates useful for treating abnormal cellular proliferation
WO2002042318A2 (en) * 2000-10-25 2002-05-30 Mayo Foundation For Medical Education And Research Transcobalamin receptor binding conjugates for neutron capture therapy
US20030018009A1 (en) * 2001-06-20 2003-01-23 Collins Douglas A. Adenosyl-cobalamin fortified compositions
JP2005508332A (ja) * 2001-09-28 2005-03-31 メイオウ・フアウンデーシヨン・フオー・メデイカル・エジユケイシヨン・アンド・リサーチ 薬剤を送達するための、輸送タンパク質とコンジュゲートコバラミンとの同時投与

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007505144A (ja) * 2003-09-10 2007-03-08 インフラブロック・ファーマシューティカルス・インコーポレーテッド 抗腫瘍療法のためのコバラミン結合体
JP2013129670A (ja) * 2007-08-30 2013-07-04 Technische Univ Muenchen 癌の画像化と処置
JP2016528299A (ja) * 2013-08-22 2016-09-15 ロバート・ドイルＲｏｂｅｒｔ ＤＯＹＬＥ ビタミンｂ１２および内因子を含む組成物およびその使用方法

Also Published As

Publication number Publication date
EP1435973A1 (en) 2004-07-14
EP1435973A4 (en) 2007-05-02
CA2461705A1 (en) 2003-04-03
WO2003026674A1 (en) 2003-04-03
US20030144198A1 (en) 2003-07-31
US20050249663A1 (en) 2005-11-10

Similar Documents

Publication Publication Date Title
JP2005508332A (ja) 薬剤を送達するための、輸送タンパク質とコンジュゲートコバラミンとの同時投与
US7531162B2 (en) Transcobalamin receptor binding conjugates useful for treating abnormal cellular proliferation
US20020042394A1 (en) Cobalamin compounds useful as antibiotic agents and as imaging agents
JP4625637B2 (ja) 活性物質送達系及び活性物質を保護し投与する方法
US9931407B2 (en) Silicon based drug conjugates and methods of using same
JP6510494B2 (ja) 腎薬物標的化のためのペプチドおよびペプチド−活性成分の接合体
ES2229355T3 (es) Procedimiento para la fabricacion de complejos medicamentosos.
JP4794735B2 (ja) ビタミンｂ１２誘導体及びそれらの製造方法
US20020049155A1 (en) Cobalamin compounds useful as cardiovascular agents and as imaging agents
CA3043464A1 (en) Di-sulfide containing cell penetrating peptides and methods of making and using thereof
US11020410B2 (en) Self-assembled gels formed with anti-retroviral drugs, prodrugs thereof, and pharmaceutical uses thereof
WO2013170272A2 (en) Site-specific labeling and targeted delivery of proteins for the treatment of cancer
JP2023537066A (ja) トランス－シクロオクテン生体直交型薬剤並びに癌及び免疫療法における使用
WO2002042318A2 (en) Transcobalamin receptor binding conjugates for neutron capture therapy
CN114163479B (zh) 一类治疗癌症用的铂类化合物及其制备方法
AU2002330153B2 (en) Coadministration of transport protein with conjugated cobalamin to deliver agents
EP1754712A2 (en) Transcobalamin binding conjugates useful for treating abnormal cellular proliferation
AU2002330153A1 (en) Coadministration of transport protein with conjugated cobalamin to deliver agents
JPH09124512A (ja) 肝臓ターゲティングのための水溶性の薬物−プルラン結合体製剤
EP3310787B1 (en) Taggable heteroaromatic drugs and conjugates thereof
AU2003204343B2 (en) Vitamin B12 derivatives and methods for their preparation
AU4490099A (en) Vitamin B12 derivatives and methods for their preparation

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20050929

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20050929

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20090519

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20091020